Refining Conditioning Intensity for Older Adults Undergoing Transplant
-
By
February 11, 2026
-
1 min
Dr. Stefan Ciurea from UCI Health presented significant findings at the 2025 ASH Annual Meeting, highlighting a study of over 11,000 patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) undergoing transplantation. This research confirms the benefits of reduced-intensity conditioning regimens in elderly patients, particularly those using fludarabine and melphalan. Emphasizing the importance of age, physiologic resilience, and toxicity risks, Ciurea advocates for future studies aimed at personalizing conditioning strategies to improve outcomes in this vulnerable group of patients.
1. Study involved over 11,000 patients with AML and MDS. 2. Fludarabine and melphalan are key conditioning agents for older adults. 3. Importance of age and physiologic reserve in regimen decisions. 4. Future studies are needed for personalized conditioning. 5. Research contributes to evolving transplant strategies in hematology.
Listen Tab content
